Supplementary file 1_Impact of Bifidobacterium infantis supplementation on growth, health

A dataset from a randomized controlled trial evaluating the impact of Bifidobacterium infantis strain Bi-26 supplementation on growth and health outcomes in underweight infants. The trial involved 40 infants aged 30–120 days with a weight-for-age Z score below -2, receiving daily oral Bi-26 or placebo for 28 days with follow-up to day 90. Data includes fecal B. infantis levels, microbiome composition, metabolome, cytokine profiles, adverse events, and growth measurements.

Use Cases

• Analyze probiotic engraftment efficacy based on fecal B. infantis levels measured at day 28 and day 56
• Compare adverse event rates between treatment and placebo groups based on reported event counts
• Investigate associations between Bifidobacterium-community types and health outcomes based on microbiome composition data
• Evaluate transient changes in microbiome function and metabolite abundance mentioned in the results

Strengths

• Data originates from a double-blind, randomized, placebo-controlled trial (NCT05952076), a rigorous study design
• Includes multiple biological assessments: total B. infantis levels, microbiome, metabolome, and cytokine profiles
• Provides specific adverse event counts (17 vs. 49 events) and percentages (40% vs. 80% of infants) for comparison

Limitations

• Row count is unknown, which may limit suitability assessment
• Column-level documentation is absent; field semantics must be inferred after download
• The intended sample size was 396 infants, but the study was terminated early with only 40 participants, limiting statistical power

Provenance

Source

Clinical trial NCT05952076, uploaded to figshare by Janie Parrino

Collection Method

Data collected from a double-blind, randomized, placebo-controlled clinical trial.

Time Range

Trial duration from baseline to day 90 follow-up.

Freshness

Last updated 2026-04-29 05:57:37; freshness should be verified

Geography

Infants from Pakistan.